Search - tctmd.com

Displaying 21 - 40 of 228

Sort: Relevancy | Date

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

Caitlin E. Cox

March 16, 2021

News Daily News

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

Michael O'Riordan

March 01, 2021

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

Presentation TCT 2020

The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus Biodegradable Polymer Drug-Eluting Stents after percutaneous coronary intervention in patients with Acute Coronary Syndrome

Presenter: Hyo-Soo Kim

October 17, 2020

Presentation TCT 2020

HOST-REDUCE-POLYTECH-ACS: A Randomized Trial of Durable Polymer vs Bioabsorbable Polymer DES in Patients With Acute Coronary Syndromes

Presenter: Hyo-Soo Kim

October 17, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Michael O'Riordan

July 07, 2020

Podcast TCTMD Talking Points

Onyx ONE: Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

April 15, 2020

News Conference News CRT 2020

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

Michael O'Riordan

February 25, 2020

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

L.A. McKeown

February 25, 2020

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

Presentation TCT 2019

IDEAL-LM: A Randomized Trial of a Bioabsorbable Polymer DES With 4-Month DAPT vs. a Durable Polymer DES With 12-Month DAPT in Patients With Left Main Coronary Artery Disease

Presenter: Robert-Jan Van Geuns

September 26, 2019

Presentation TCT 2019

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

Presenter: Stephan Windecker

September 26, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Conference News ESC 2019

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

Caitlin E. Cox

September 10, 2019

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

Presentation

Biodegradable-Polymer Synergy vs Durable-Polymer Xience for PCI in Clinical Practice

August 14, 2019

News Industry News

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

July 23, 2019

Advertisement

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

No Harm, No Help With Bioabsorbable-Polymer Stents: Registry

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

The HOST-Reduce-Polytech-ACS trial: Durable Polymer versus Biodegradable Polymer Drug-Eluting Stents after percutaneous coronary intervention in patients with Acute Coronary Syndrome

HOST-REDUCE-POLYTECH-ACS: A Randomized Trial of Durable Polymer vs Bioabsorbable Polymer DES in Patients With Acute Coronary Syndromes

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Polymer-Free DES Hold No Long-term Advantage: ISAR-TEST-5

Onyx ONE: Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

PCI-Related MIs Not Linked to Mortality at 1 Year: Onyx ONE

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

IDEAL-LM: A Randomized Trial of a Bioabsorbable Polymer DES With 4-Month DAPT vs. a Durable Polymer DES With 12-Month DAPT in Patients With Left Main Coronary Artery Disease

Onyx ONE: A Randomized Trial of a Durable-Polymer Drug-Eluting Stent vs. a Polymer-Free Drug-Coated Stent in Patients at High Risk of Bleeding Treated With 1-Month DAPT

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

BIOSTEMI: Ultrathin-Strut Orsiro Superior to Xience for 1-Year TLF After Primary PCI

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Biodegradable-Polymer Synergy vs Durable-Polymer Xience for PCI in Clinical Practice

SINOMED® Concludes Enrollment of the PIONEER III Randomized, Pivotal Study of the BuMA Supreme® Coronary Drug-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content